Li Q, et al. - Researchers here sought to determine the clinicopathologic factors that predict the outcome of routine trastuzumab plus chemotherapy in HER2 positive advanced gastric cancer (AGC). They observed that regardless of most of the clinicopathological factors, the addition of trastuzumab to chemotherapy was effective and safe in real-world setting in Chinese patients with HER2 positive AGC. They recommended further studies to improve the prognosis of HER2 positive patients with liver metastasis or poor performance status.